Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex

被引:1076
|
作者
Brugarolas, J
Lei, K
Hurley, RL
Manning, BD
Reiling, JH
Hafen, E
Witter, LA
Ellisen, LW
Kaelin, WG [1 ]
机构
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02116 USA
[4] Dartmouth Coll, Dept Med & Biochem, Dartmouth Med Sch, Hanover, NH 03755 USA
[5] Dartmouth Coll, Dept Sci Biol, Hanover, NH 03755 USA
[6] Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA
[7] Univ Zurich, Inst Zool, CH-8057 Zurich, Switzerland
[8] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA
关键词
tuberous sclerosis complex; TSC1; TSC2; REDD1/RTP801; mTOR; hypoxia;
D O I
10.1101/gad.1256804
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Mammalian target of rapamycin (mTOR) is a central regulator of protein synthesis whose activity is modulated by a variety of signals. Energy depletion and hypoxia result in mTOR inhibition. While energy depletion inhibits mTOR through a process involving the activation of AMP-activated protein kinase (AMPK) by LKB1 and subsequent phosphorylation of TSC2, the mechanism of mTOR inhibition by hypoxia is not known. Here we show that mTOR inhibition by hypoxia requires the TSC1/TSC2 tumor suppressor complex and the hypoxia-inducible gene REDD1/RTP801. Disruption of the TSC1/TSC2 complex through loss of TSC1 or TSC2 blocks the effects of hypoxia on mTOR, as measured by changes in the mTOR targets S6K and 4E-BP1, and results in abnormal accumulation of Hypoxia-inducible factor (HIF). In contrast to energy depletion, mTOR inhibition by hypoxia does not require AMPK or LKB1. Down-regulation of mTOR activity by hypoxia requires de novo mRNA synthesis and correlates with increased expression of the hypoxia-inducible REDD1 gene. Disruption of REDD1 abrogates the hypoxia-induced inhibition of mTOR, and REDD1 overexpression is sufficient to down-regulate S6K phosphorylation in a TSC1/TSC2-dependent manner. Inhibition of mTOR function by hypoxia is likely to be important for tumor suppression as TSC2-deficient cells maintain abnormally high levels of cell proliferation under hypoxia.
引用
收藏
页码:2893 / 2904
页数:12
相关论文
共 50 条
  • [41] PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma
    Roldan-Romero, J.
    Beuselinck, B.
    Santos, M.
    Rodriguez-Moreno, J.
    Lanillos, J.
    Calsina, B.
    Gutierrez, A.
    Tang, K.
    Caleiras, E.
    Montero-Conde, C.
    Cascon, A.
    Robledo, M.
    Garcia-Donas, J.
    Rodriguez-Antona, C.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 1678 - 1678
  • [42] Evidence for population variation in TSC1 and TSC2 gene expression
    Jentarra, Garilyn M.
    Rice, Stephen G.
    Olfers, Shannon
    Saffen, David
    Narayanan, Vinodh
    BMC MEDICAL GENETICS, 2011, 12
  • [43] A hypomorphic allele of Tsc2 highlights the role of TSC1/TSC2 in signaling to AKT and models mild human TSC2 alleles
    Pollizzi, Kristen
    Malinowska-Kolodziej, Izabela
    Doughty, Cheryl
    Betz, Charles
    Ma, Jian
    Goto, June
    Kwiatkowski, David J.
    HUMAN MOLECULAR GENETICS, 2009, 18 (13) : 2378 - 2387
  • [44] Mutations in TSC1 and TSC2 Are Associated with High Tumor Mutational Burden and Therapeutic Options
    Gay, Laurie M.
    Elvin, Julia A.
    Suh, James
    Vergilio, Jo-Anne
    Ramkissoon, Shakti H.
    Schrock, Alexa
    Ali, Siraj M.
    Fabrizio, David
    Frampton, Garrett
    Miller, Vincent
    Stephens, Philip
    Ross, Jeffrey
    LABORATORY INVESTIGATION, 2017, 97 : 457A - 457A
  • [45] Loss of heterozygosity of TSC2 and TSC1 gene in perivascular epitheliold cell tumor (PEComa)
    Pan, CC
    Chung, MY
    LABORATORY INVESTIGATION, 2006, 86 : 153A - 154A
  • [46] Molecular analysis of the TSC1 and TSC2 tumour suppressor genes in sporadic glial and glioneuronal tumours
    Parry, L
    Maynard, JH
    Patel, A
    Hodges, AK
    von Deimling, A
    Sampson, JR
    Cheadle, JP
    HUMAN GENETICS, 2000, 107 (04) : 350 - 356
  • [47] TSC1 And TSC2 Differentially Modulate Actin Cytoskeleton And Motility
    Goncharova, E. A.
    Goncharov, D. A.
    Krymskaya, V. P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181
  • [48] Deep phenotyping of patients with Tuberous Sclerosis Complex and no mutation identified in TSC1 and TSC2
    Peron, Angela
    Vignoli, Aglaia
    La Briola, Francesca
    Morenghi, Emanuela
    Tansini, Lucia
    Alfano, Rosa Maria
    Bulfamante, Gaetano
    Terraneo, Silvia
    Ghelma, Filippo
    Banderali, Giuseppe
    Viskochil, David H.
    Carey, John C.
    Canevini, Maria Paola
    EUROPEAN JOURNAL OF MEDICAL GENETICS, 2018, 61 (07) : 403 - 410
  • [49] The mTOR Independent Function of Tsc1 and FNIPs
    Sager, Rebecca A.
    Woodford, Mark R.
    Mollapour, Mehdi
    TRENDS IN BIOCHEMICAL SCIENCES, 2018, 43 (12) : 935 - 937
  • [50] Mutational analysis of TSC1 and TSC2 genes in Japanese patients with tuberous sclerosis complex
    Zhang, H
    Nanba, E
    Yamamoto, T
    Ninomiya, H
    Ohno, K
    Mizuguchi, M
    Takeshita, K
    JOURNAL OF HUMAN GENETICS, 1999, 44 (06) : 391 - 396